Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
2 Top Healthcare Stocks Defying the Bear Market
08:10am, Friday, 07'th Apr 2023
The demand for medical product distribution is set to grow and McKesson is the clear leader of the industry. Sanofi's stacked product portfolio and pipeline should power double-digit annual earnings g
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
05:48am, Thursday, 30'th Mar 2023
Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (COPD). The medicine could top $3 billion in annual revenue for Sa
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
01:26pm, Monday, 27'th Mar 2023
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies'
Regeneron, Sanofi Look for Billions From COPD Drug
10:00am, Saturday, 25'th Mar 2023
The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.
Could This Label Expansion Be a Growth Catalyst for Sanofi Stock?
08:43am, Saturday, 25'th Mar 2023
Dupixent was proven to be effective at treating a condition that causes chronic hives. The indication could generate $600 million in annual revenue for Sanofi and Regeneron to share.
Is Sanofi Stock a Buy Now?
07:15am, Saturday, 25'th Mar 2023
Sanofi is reducing the price of its most important insulin product. A pending acquisition could help pick up the slack in diabetes care.
Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough
02:17pm, Friday, 24'th Mar 2023
Regeneron is scaling new highs after a lung disease breakthrough and analyst upgrade. The post Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough appeared first on Investor's Busines
ETFs in Focus on Sanofi and Regeneron's COPD Drug Data
09:12am, Friday, 24'th Mar 2023
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.
Sanofi (SNY) Moves 6.0% Higher: Will This Strength Last?
04:36am, Friday, 24'th Mar 2023
Sanofi (SNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study
03:14pm, Thursday, 23'rd Mar 2023
Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease.
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
02:31pm, Thursday, 23'rd Mar 2023
Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say "exceeded expectations."
Sanofi's blockbuster Dupixent drug clears major trial
10:43am, Thursday, 23'rd Mar 2023
French pharma multinational Sanofi's Dupixent drug has achieved impressive results in a late-stage trial to treat chronic obstructive pulmonary disease (COPD), aka ‘smoker's lung'. Developed jointly
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
09:03am, Thursday, 23'rd Mar 2023
Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
07:42am, Tuesday, 21'st Mar 2023
Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.
ACER's Stock Down on Failure of Phase II Study, Cash Updates
01:46pm, Monday, 20'th Mar 2023
ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.
